VOLUME 33

SUBJECT INDEX

ACE inhibitors, 573
ACTH, 335
AP5, 713
Acetylcholine, 501
Acetylcholine release, 109
Acetylcholinesterase, 485
Acetylsalicylic acid, 253
Acidosis, 563
Acoustic startle response, 415, 667
Activity, 633
Addictions, 765
α_2-Adrenergic receptors, 233
Adrenocortical system, 85
Adverse side-effects, 923
Age-dependent reductions, 489
Aggressiveness, 85
Agonist, 919
Alarm pheromone, 435
Alcohol, 407, 797
Alcohol intake, 493
Alcoholic blackouts, 27
Aldosterone, 401
Allantoxanamide, 367
N-Allylnormetazocine, 717
Amfonelic acid, 741
Amnesia, 27, 241
Amphetamine, 269, 273, 507, 567, 847, 909
d-Amphetamine, 115, 139, 181, 511, 527, 721, 733, 741
l-Amphetamine, 181
Amylase, 663
Analgesia, 555, 793
Angiotensin II, 401
Anorexia, 181
Antagonist, 919
Antidepressants, 93, 755
Antihistamine, 245
Antihypertensive agents, 923
Anxiety, 227, 371, 649
Anxiolytic/anxiogenic-5-HT, 197
Apomorphine, 81, 115, 123, 139, 387, 423, 595, 609, 709
Appetite, 721
Area postrema, 847
Arousal, 431
Attachment, 533
Autism, 839
Autonomic, antinociceptive and behavioral responses, 245, 717
Autoradiography, 69
Autoreceptors, 139
Avoidance, 549

Barbiturate hypnosis, 701
Behavior, 69, 115, 415, 435, 839
Behavioral, 811
Behavioral dependence, 559
Behavioral 'despair', 371
Behavioral response, 489
Behavioral thermoregulation, 315
Behavioural supersensitivity, 609
Benzodiazepine abuse, 393
Benzodiazepine-GABA receptor complex, 601
Benzodiazepine receptor, 227
Benzodiazepines, 31, 205, 261, 303, 435, 465, 633, 721, 859
Beta adrenergic agonist, 493
Bicuculline, 285
Bioflavonoid, 523
Black and white test box, 197
Blood levels, 63
Blood pressure, 381, 923
Body temperature, 667, 781
Body weight, 45
Boundary model, 815
Brain, 797
Brain dialysis, 109
Brain mast cells, 75
Brain stimulation reward, 725
Breathhold duration, 481
Bremazocine, 375
Bromocriptine, 829
α-Bungarotoxin, 469, 679
Butorphanol, 355

β-CCE, 227
CCK, 591
CGS 17867A, 303
CM 30366, 655
m-CPP, 265
Caffeine, 55, 99, 299
Calcium channel blocking agents, 923
Calcium channel inhibitors, 507
Calcium-induced LTP, 713
Cannula, 453
Capsaicin, 843, 899
Captopril, 573, 899
Carbachol, 663
Carbamate, 811
Carbidopa, 139
β-Carboline, 465
Carbon monoxide, 481, 853
Cardiomyopathy, 633
Cat, 115, 627
Catalepsy, 93, 705, 915
Catecholaminergic drugs, 567
Catecholamines, 381
Cathinone, 299
Caudate nucleus, 511
Caudate putamen, 175, 309, 453
Chlordiazepoxide, 261, 285, 859
Chloride flux, 465
p-Chloroamphetamine (PCA), 343
Chlorpromazine, 567
Choice behavior, 733
Choice reaction time, 923
Cholecystokinin, 637
Choline acetyltransferase, 485
Choline uptake, 109, 131
Cholinergic neurotransmission, 895
Cholinergic systems, 131
Chronic, 559
Chronic L-DOPA, 139
Cigarette smokers, 853
Cigarette smoking, 189
Cigarettes, 815, 853
Circadian rhythms, 257, 291
Cisplatin, 219, 627
Clomipramine, 265
Clonidine, 233, 291, 721
Cocaine, 99, 167, 197, 443, 453, 527, 725, 733, 829, 859, 903
Cocaine abuse, 393
Coexistence, 127
Cognition, 573
Cold-restraint stress, 563
Color discrimination, 923
Comfort, 839
Complex stimulus control, 584
Conditioned avoidance, 895
Conditioned emotional response, 27
Conditioned fear, 477
Conditioned location avoidance, 913
Conditioned place preference, 281, 765
Conditioned taste aversion, 219, 269, 847
Consumption, 407
Continuous infusions, 443
Convulsions, 31, 787
Copulatory behavior, 81
Corticosterone, 55, 265, 781
Cross-tolerance, 781
Crowding, 335
Cues, 549
Cumulative dosing, 205

D1, 501
D_1, 919
D-1 dopamine receptors, 139
D-1 receptors, 41
D2, 501
D2 dopamine receptors, 123
D_2, 919
D_2 receptors, 21, 721
D-2 dopamine receptors, 139
D-2 receptors, 41
D1 and D2 receptors, 273
D-Pro^2-D-Trp^{7,9}-substance P, 843
DA neuron activity, 741
DOPAC, 477, 741
DOPAC/DA ratio, 741
DRL 72-sec schedule of reinforcement, 641
Day-old chicks, 881, 889
Deep pressure, 839
Deermouse, 309
Deoxycorticosterone acetate, 401
Depression, 649
Desipramine, 749
Development, 325, 415, 539, 567
Dexamphetamine, 489
Diazepam, 31, 205, 227, 465, 477, 755
Differential housing, 387
Diltiazem, 507
Dinitrophenol, 881, 889
Discrimination stimulus, 453, 527
Dissociation, 215
Dogs, 533
Domestication, 85
Dopamine, 1, 21, 31, 105, 273, 299, 309, 371, 501, 595, 741
^{3}H-Dopamine, 397
Dopamine autoreceptors, 387
Dopamine receptors, 915
Dopaminergic, 847, 919
Dopaminergic hypersensitivity, 123

Dorsal bundle, 729
Dorsal immobility response, 321
Dorsal striatum, 321
Dose-response relationship, 115
Drinking, 7, 335, 407, 805
Drug addiction, 903
Drug discrimination, 299, 355, 761, 875, 909
Drug interaction, 99
Drug preference, 205
Drug reinforcement, 765
Drug state aversion, 913
Drug-taking behavior, 903
Duodenal distension, 253

ECS, 749
EDRF, 519
EEG, 157
EMG, 127
Eating behavior, 257, 507
Embryology, 325
Emesis, 627
Emotional stress, 85
Emotions, 431
Endogenous opioids, 697
Endorphins, 147, 325, 533, 839
β-Endorphin, 545
Enkephalins, 325
Epinephrine, 545
Estradiol, 321, 615
Estrogens, 45
Ethanol, 27, 269, 315, 335, 407, 581, 793, 797, 867
Ethanol abuse, 393
Ethanol antagonists, 601
Ethanol reinforcement, 601
Ethanol tolerance, 729
Ethosuximide, 11
Ethylalcohol, 523
Ethylketocyclazocine, 355
Excitatory amino acids, 175
Exercise, 811
Exploration, 371

FG 7142, 465, 601
Fathead minnows, 435
Feeding, 303
Female, 615
d-Fenfluramine, 721
Filter ventilation, 815
Fixed-consecutive-number schedule, 361
Fixed-ratio schedule, 777
Food, 621
Food and water consumption, 167
Food deprivation, 375
Food deprivation level, 567
Food intake, 375, 585, 787
Food preference, 17
Forced-swim test, 649
Forgetting, 51
Forward conditioning, 431
Frontal cortex, 109, 485
Functional antagonism, 821
Functional gonadectomy, 45

GABA, 269, 285, 787
GABA-A receptors, 497
Gangliosides, 797
Gastric ulcers, 563
Gastrin, 591
Gastrointestinal peptides, 591
Genetic differences, 793
Genetics of nicotine response, 469
Globus pallidus, 321
Glucocorticoids, 219
Glycoproteins, 797
Grooming, 17, 555
Grouped housing, 335, 903
Growth, 325

HCl, 563
HPLC, 309
5-HT, 127, 371
5-HT agonists, 691
5-HT receptor antagonists, 329
5-HT receptors, 761
5-HT_{1A} receptor agonism, 821
5-HT_{1A} receptor subtype, 329
5-HT_2 receptor, 349
Haloperidol, 93, 705, 741, 847
Hamsters, 633
Head and body shakes, 75
Heart rate, 481, 667
Hepatoprotection, 523
Heroin, 903
Hibernation, 309
Hippocampus, 109, 511, 749
Hole blocking, 815
Homing, 539
Hot-plate test, 459
Human, 205, 481
Human subjective effects, 443
6-Hydroxydopamine, 729
5-Hydroxyindoleacetic acid, 257, 349
p-Hydroxynorephedrine, 423
Hyperactivity, 367
Hyperglycemia, 459
Hypertension, 923
Hypomotility, 423
Hypothalamus, 507
Hypothermia, 315, 633, 793
Hypoxia, 241

Imipramine, 725
Immobility, 227
Implant, 63
Inbred strains, 63
Independent feeding, 567
Indomethacin, 253
Ingestion, 7
Interresponse-time-greater-than-*t* schedule, 777
Intracerebroventricular, 697
Intracerebroventricular Compound 48/80, 75
Intrathecal injection, 843
Intravenous self-administration, 903
Inverse benzodiazepine agonists, 601
Ionizing radiation, 549
Irreversible antagonist, 895
Isolated housing, 903
Isolated rat pancreatic acini, 663
Isolation, 335, 371
Isolation-induced fighting, 387
Isoproterenol, 493

Jump latency, 459

KK-3, 843
Kappa opioid receptor agonists, 375
Ketanserin binding, 349

L364,718, 637
LSD-25, 69
LY 171555, 501, 511, 919
Learned helplessness, 649
Lever press, 147, 361
Lidocaine, 527
Limbic brain, 69
Lindane, 787
Lithium chloride, 219
Liver, 797
Liver blood flow, 621
Liver damage, 523
Local anesthetics, 527
Locomotion, 17, 371, 423, 497, 595
Locomotor activity, 139, 167, 291, 507, 637, 667, 741, 749, 927
Long-term memory consolidation, 889
Loperamide, 407
Lorazepam, 627
Low-yield cigarettes, 815
Lower lip retraction, 821

MBDB, 105
MDE, 909
MDMA, 105, 741, 909
MDMA-induced serotonin depletion, 641
MIF-1, 261
MK-212, 781
5-MeODMT, 781
Male and female Wistar rats, 361
Male sexual behavior, 691
Marijuana, 481
Meal pattern analysis, 21
Meals, 621
Mecamylamine, 919
Medial prefrontal cortex, 453
Median raphe nucleus, 309
Mefenamic acid, 253
Memory, 481, 511
Memory enhancement, 51
Memory retrieval, 51
Memory stages, 881
Mesocortical/mesolimbic, 741
Mesolimbic, 595
Mesoprefrontal dopamine neurons, 477
Metabolism, 621
Methamphetamine, 93, 423
N-Methyl-D-aspartic acid, 485
α-MethylDOPA, 139
Methylenedioxyamphetamine (MDA), 343
Methylenedioxymethamphetamine (MDMA), 343
±3,4-Methylenedioxymethamphetamine, 641
Methylnaltrexone, 407
α-Methyl-p-tyrosine, 41
Methylscopolamine, 913
Metoclopramide, 273
Mice, 139, 197, 315, 705, 793, 915, 927
Microdialysis, 257
Microwaves, 131
Minaprine, 655
Monoamine oxidase inhibitors, 655
Monosodium glutamate, 881
Morphine, 219, 355, 407, 533, 539, 765, 899
Morphine dependence, 875
Motion sickness, 627
Motoneurone, 127
Motor activity, 387
Motor behavior, 41, 175
Mouse habituation, 573
Mouse-killing behavior, 655
Muscarinic acetylcholine receptor, 895

Muscarinic receptors, 131
Muscimol, 497
Muscular twitches, 497

N-0437, 21, 721
N-OH MDA, 909
NMDA receptors, 713
NSAIDs, Prostaglandins, 253
NaCl, 335
$NaHCO_3$, 563
Nalmefene, 721
Nalorphine, 355
Naloxone, 147, 261, 325, 533, 539, 805, 927
Naloxone insensitive, 215
Naloxone-precipitated withdrawal, 899
Naloxone-sensitive, 215
Naltrexone, 17, 131, 355, 407, 697, 721, 793, 839, 875
Neonatal mouse, 497
Neuraminic acid, 797
Neurochemicals, 435
Neurohypophyseal peptide, 555
Neuroleptics, 31, 45, 709
Neuronal response, 489
Neuropeptide, 7
Neurosteroids, 701
Neurotensin, 7
Neurotoxicity, 69, 105, 489
Nicotinamide, 915
Nicotine, 1, 63, 197, 469, 559, 591, 621, 663, 667, 679
Nicotine dependence, 815
Nicotinic, 919
Nicotinic cholinergic receptors, 679
Nicotinic receptors, 469
Nifedipine, 923
Nigrostriatal, 741
Nikethamide, 299
Nociception, 459
Nociceptive tests, 253
Nonappetitive behavioral activation, 567
Nonhuman primates, 923
Noradrenaline, 371
Norepinephrine, 85, 595, 729
Normal volunteers, 205
Normoglycemia, 459
Nose-poke, 147
Nucleus accumbens, 321, 453, 595
Nucleus basalis of Meynert, 485
Nucleus reticularis pontis caudalis, 233

8-OH-DPAT, 329, 627, 781
Ontogenetic ethopharmacology, 497
Ontogeny, 555, 567
Open field activity, 55
Open-field behavior, 555
Operant, 811
Operant behavior, 709
Opiate withdrawal syndrome, 875
Opiates, 721, 793
Opioid, 245
Opioid antagonist, 875
Opioid peptides, 839
Opioid receptor, 325, 355, 793
Opioids, 325, 407, 533, 805
Oral, 167
Oral drug, 393
Oral movement, 501
Ostariophysan fishes, 435
Ouabain, 881
Ovariectomy, 45, 123
Oxotremorine, 27, 545
Oxytocin, 555
Oxytocin antagonists, 81

PCP, 281
pH, 663
3-PPP, 387
Palatability, 17, 303, 805
Pantethine, 585
Para-chlorophenylalanine, 655
Paraventricular nucleus, 257, 507
[^{3}H]-Paroxetine, 105
Passive avoidance, 241
Passive avoidance learning, 881
Passive avoidance memory, 485
Paw tremor and other behaviors, 75
Pentazocine, 245, 355
Pentobarbital, 527, 927
Pentylenetetrazol, 11, 31
Peptides, 261
Performance, 549
Perinatal, 867
Pharmacogenetics, 667, 679
Pharmacological interactions, 245, 717
Phencyclidine, 281
Phosphodiesterase inhibitor, 875
Physical dependence, 559
Physiological responses, 829
Picrotoxin, 269, 285, 749
Pigeons, 11, 527, 777
Pigs, 839
Pilocarpine, 501
Place conditioning, 273
Plasma concentrations, 167
Plasma corticosterone, 477
Plasma renin activity, 401
Play, 539, 697
Positive affect, 765
Pregnenolone sulfate, 701
Prenatal stress, 55
Pretest treatments, 545
Preweanling, 415
Preweaning rats, 567
Procaine, 527
Proestrus, 615
Prolactin, 265
Propylbenzilylcholine mustard (PrBCM), 895
Pseudoconditioning, 431
Psychomotor stimulants, 641
Puff volume changes, 189
Puff-by-puff analysis, 189
Pyrazole, 797

Quasi-withdrawal syndrome, 875
Quaternary naltrexone, 697
Quinpirole, 273, 721

Ro 15-1788, 227, 285, 477
Ro 15-4513, 269, 601, 777
Ro 23-0364, 303
RU24969, 761
Rabbits, 431
Radial-arm maze, 131, 919
Radial maze, 511
Raphe lesions, 655
Rat, 63, 75, 93, 157, 241, 265, 273, 285, 291, 303, 415, 423, 453, 485, 501, 539 573, 615, 691, 709, 733, 749, 761, 913
Rat aorta, 519
Rate dependency, 99
Rearing, 17
Receptor, 1, 435
Receptor binding, 139
Rectal temperature, 55
Reinforcement, 147, 859
Relaxation, 839
Renin-angiotensin system, 493
Repeated-testing, 705
Repeated training, 889
Reserpine, 41
Respiratory rate, 667
Response accuracy, 361
Response difficulty, 147
Response rates, 361
Restraint stress, 755
Reticular formation, 233
Retrieval, 27
Retroactive interference, 545
Reward, 805
Rodent, 325, 811
Rotation, 609
Rush, 443

SCH 23390, 273, 501, 709
SKF 10,047, 355
SKF 38393, 273, 501, 919, 511, 139
SQ29, 852, 573
SR 95191, 655
ST-91, 233
Saccharin intake, 805
Saccharin preference, 755
Saline drinking, 285
Salt appetite, 401
Satiety, 21, 585
Schedule-controlled behavior, 99, 777
Schedule-induced polydipsia, 393
Scopolamine, 109, 709
Scopolamine amnesia, 51
Scopolamine hydrobromide, 361
Scopolamine methylbromide, 361
Seizure, nicotine-induced, 469
Seizures, 11
Selective attention, 733
Self-administration, 407, 859
Self-stimulation, 147, 725
Sensory control, 189
Sensory-evoked potentials, 157
Serotonergic hypersensitivity, 349
Serotonin, 85, 105, 241, 257, 309, 349, 415, 615, 627, 655
Serum cholesterol, 381
Serum corticosterone, 329
Sex differences, 381
Sexual behavior, 867
Sialic acid, 797
Sialidase, 797
Signal Detection Analysis, 584
Smoke handling behavior, 189
Smoking, 481, 621, 815
Smoking topography, 481, 815, 853
Social behavior, 533, 539, 697
Social deprivation, 533
Social stress, 335
Solvent abuse, 157
Somatic, 325
Somatostatin, 585
Sorbitol, 797
Spinal cord, 233
Spiroperidol, 123
Spontaneous motor activity, 109
Sprague-Dawley rats, 375
Squeeze chute, 839
Squirrel monkey, 581
Startle, 233, 415

Stereoselectivity, 691
Stereotyped behavior, 343
Stereotypy, 123, 139, 167, 423
Straw-climbing behavior, 227
Straw-suspension, 227
Streptozotocin, 459
Stress, 31, 219, 349, 431, 633, 649
Striatal dopamine release, 397
Striatum, 1, 397, 489
Subcutaneous, 167
Subjective effects, 481
Subjective responses, 829
Substance P, 843, 899
Substance P-induced behavior, 843
Substance P releaser, 843
Substantia nigra pars compacta, 321
Sucrose, 721
Sucrose reinforcement, 601
Sulpiride, 45, 501
Supersensitivity, 139, 655
Suprachiasmatic nucleus, 309
Sustained attention, 733
Sustained release, 63
Syrian hamsters, 721

TBPS, 465
TRH, 127
T's and Blues, 245, 717
Tail flick, 459
Tail-immersion test, 459
Tail wagging, 533
Tail withdrawal, 459
Tardive dyskinesia, 123
Taste preference, 805
Temperature, 139, 261
Temperature gradient, 315
Temperature regulation, 787
Testosterone, 867
Δ^9-Tetrahydrocannabinol, 397
Theophylline, 609
Thermoregulation, 315
Tifluadom, 375
Time-dependent sensitization, 31
T-maze, 573
Tobacco, 815
Tolerance, 181, 443, 559, 781
Toluene, 157
Torpor, 309
Tricyclic antidepressants, 725
Triglycerides, 381
Tripelennamine, 245, 717
l-Tryptophan, 401
Tuberoinfundibular, 741
Type-1 diabetes, 519
Type-2 diabetes, 519
Tyr-MIF-1, 261

U-50,488H, 215, 375
Uric acid, 367
Uricase inhibitor, 367
Urinary output, 375

Valproate, 285
Variability of subject sensitivity, 189
Ventral cochlear nucleus, 233
Visceral pain, 253
Vomiting 627

WDS, 127
Water intake, 7, 709
Water-maze, 573
Weakly reinforced passive avoidance learning, 889
Weight loss, 591
Withdrawal, 559

X-112, 299
Xylazine, 627

Yohimbine, 459

Zolpidem, 303

AUTHOR INDEX

Abucham, J., 585
Ahlenius, S., 691
Al-Khatib, Iz., M. H., 93
Altan, V. M., 519
Amit, Z., 269
Anderson, G. J., 913
Antelman, S. M., 31
Aprison, M. H., 349
Argiolas, A., 81
Arvidsson, L.-E., 691
Aulakh, C. S., 265

Baker, J. D., 7
Baldry, A. G., 189
Bansinath, M., 459
Baptista, T., 45
Barr, G. A., 567
Barrera, C. M., 367
Bates, E. H., 435
Battaglia, M., 927
Baulieu, E.-E., 701
Baumeister, A. A., 7
Beart, P. M., 139
Bédard, P. J., 127
Bedichek, R. C., 315
Belluzzi, J. D., 147
Benedetti, M., 713
Beninger, R. J., 273
Benowitz, N. L., 621
Berendsen, H. H. G., 821
Bhargava, H. N., 375
Blampied, N. M., 913
Błaszczyńska, E., 329
Bleck, V., 465
Bluet-Pajot, M.-T., 701
Bollinger-Gruber, J., 585
Borodin, P. M., 85
Boulis, N. M., 233
Bozarth, M. A., 903
Brioni, J. D., 27, 545
Broekkamp, C. L. E., 821
Budziszewska, B., 329
Burghardt, W. F., Jr., 549
Buris, L., 523
Butcher, L. L., 919
Byers, K. I., 63

Cadafalch, J., 609
Cagin, N. A., 431
Calcagnetti, D. J., 697
Campbell, S. M., 679
Capuano, C. A., 567
Carbone, J. J., 55
Carino, M. A., 131
Carney, J. M., 99
Casas, M., 609
Cassella, J. V., 233
Chait, L. D., 481
Champney, T. H., 741
Cho, A. K., 343
Cho, C. H., 563
Chowdhury, P., 591, 663
Clifton, P. G., 21
Coen, K. M., 559
Colburn, R. W., 253
Collins, A. C., 469, 667, 679
Collu, M., 81
Commissaris, R. L., 233
Concha, E., 115
Cone, E., 443
Conner, R. L., 533
Continella, G., 555
Cook, C. J., 139
Cook, L. L., 415
Coombs, D. W., 253
Cooper, S. J., 17, 21, 303, 721
Corrigall, W. A., 559
Costall, B., 197, 573
Cotler, S., 55
Cottrell, G. A., 321
Coughlan, J., 573
Crabbe, J. C., 315
Crampton, G. H., 627
Crawley, J. N., 649
Crawshaw, L. I., 315
Crowe, S. F., 881, 889
Cumming, G., 189

D'Aquila, P., 81
Dahlgren, I. L., 867
Davis, M., 233
de Beaurepaire, R., 507
Delaney, D., 777
DeLeo, J. A., 253
DeNoble, V. J., 241
Denton, D. A., 335
De Quijada, M., 45
deWit, H., 205
Dixon, M., 189
Dodman, N., 839
Dorris, R. L., 915
Dow-Edwards, D., 167
Drugan, R. C., 649
Dunlap, W. P., 367
Dygalo, N. N., 85

Edwards, D. J., 31
Ehlers, C. L., 581
Ellis, M. A., 253
Ellison, G., 69, 501
Emmett-Oglesby, M. W., 453
Erickson, C. K., 63
Ericksson, C. J. P., 867

Falk, J. L., 393
Fanselow, M. S., 697
Fennessy, M. R., 75
Ferré, S., 609
Fico, T. A., 167, 387
Fields, J. Z., 123
Finger, A. V., 811
Frank, C., 713
Frank, R. A., 725
Frankenhaeuser, M., 381
Frecker, R. C., 815
Fredrikson, M., 381
Freed, W. J., 507
Fregly, M. J., 401
Frye, G. D., 741
Fujiwara, M., 93, 397
Fukuda, T., 705
Fung, Y. K., 1

Gamagaris, Z., 167
Gardner, C. R., 761
Gessa, G. L., 81
Gibbs, M. E., 881, 889
Glennon, R. A., 909
Goeders, N. E., 859
Gomez, J., 443
Gordon, J. H., 123
Gosnell, B. A., 805
Gowans, G. C., 733
Grandin, T., 839
Grau, J. M., 609
Griffith, J. A., 787
Grilly, D. M., 733
Grogan, T. W., 733
Grover, E., 431, 633
Grupp, L. A., 493
Gudelsky, G. A., 781
Gustafsson, B., 867

Guy, A. W., 131
Guyatt, A. R., 189

Hamada, T., 355
Hamilton, M. S., 285
Haraguchi, M., 601
Hård, E., 867
Haroutunian, V., 485
Harris, R. A., 465
Harthon, C., 867
Hashizume, M., 139
Hawkins, M. F, 7
Heatherton, T. F., 815
Herling, S., 559
Hernandez, L., 45, 257
Hewson, G., 637
Hienz, R. D., 923
Hilakivi, L. A., 371
Hill, J. L., 265
Hill, R. G., 637
Hingtgen, J. N., 349
Hiramatsu, M., 343
Hoebel, B. G., 257
Hoffman, D. C., 273
Hofstetter, J. R., 349
Holloway, F. A., 99
Holtzman, S. G., 875
Horita, A., 131
Horovitz, Z. P., 573
Hosotani, R., 591, 663
Hubbell, C. L., 765
Hughes, J., 637
Hughes, R. N., 913
Hunt, W. A., 549, 847
Hunter, R. E., 367
Hutchings, D. E., 167

Ida, Y., 227, 477
Isel, F., 655
Iwata, S., 705
Izquierdo, I., 27, 545
Izumi, K., 705

Jackson, D. M., 139
Jacob, P., III, 621
Jaffe, J. H., 443, 829, 899
Jakubow, J. J., 11
Jalowiec, J. E., 697
Jané, F., 609
Jarrott, B., 75
Jarvik, M. E., 621
Jenck, F., 821
Johanson, C. E., 205
Johnson, M. P., 105
Jung, H., 51

Kameyama, T., 343, 355
Kaneto, H., 843
Kanof, P. D., 485
Karasu, C., 519
Kastin, A. J., 261
Kataoka, Y., 397
Kato, S., 895
Kehne, J. H., 233
Kelly, M. E., 197, 573
Kimura, Y., 895
King, W., Jr., 69
Kirkham, A. J. T., 189
Klemm, W. R., 797
Knopf, S., 31
Knowles, P. A., 533
Kocan, D., 31
Koo, M. W. L., 563
Koob, G. F., 595
Kosobud, A., 315
Kostowski, W., 749, 755
Kozlowski, L. T., 815
Kumor, K. M., 443, 829

Lai, H., 131
Lajtha, A., 175
Larsson, K., 691, 867
Lau, Y.-S., 1
Lee, B. L., 621
Leibowitz, S. F., 257, 567
Leighton, G. E., 637
Levin, E. D., 501, 919
Lewin, E., 465
Lewis, S. J., 75
Li, A. A., 641
Lin, L.-H., 309
Linseman, M. A., 407
Lister, R. G., 371
Ljungberg, T., 709
Logan, L., 99
Lucot, J. B., 627
Lundberg, U., 381

McAllister, K. H., 859
McCann, D. S., 733
McGaugh, J. L., 27
McGurk, S. R., 919
McKay, D., 663
McKenzie, G. M., 489
McLaughlin, P. J., 325
McMaster, S. B., 811
McNulty, M. A., 859

Maeda, Y., 343
Maickel, R. P., 181
Majchrzak, M. J., 805
Majewska, M. D., 701
Mandel, P., 655
Marek, G. J., 641
Marglin, S. H., 281, 765
Markel, A. L., 85
Marks, M. J., 667, 679
Martinez, I., 115
Mathew, J., 797
Matteucci, M. J., 157
Matthews, R. T., 741
Mattie, M. E., 281, 765
Mayeda, A. R., 349
Mejias, B., 115
Melia, K. F., 581
Melin, B., 381
Melis, M. R., 81
Meltzer, H. Y., 781
Meyer, M. E., 321
Milano, W. C., 281
Miller, L. G., 261
Mine, K., 397
Miner, L. L., 469
Mirkis, S., 859
Misaki, N., 895
Misenheimer, B. R., 909
Motles, E., 115
Murphy, D. L., 265
Murray, A., 903

Nabeshima, T., 343
Nagy, M., 7
Najam, N., 539
Nakahiro, M., 895
Nakayama, S., 355
Nash, J. F., Jr., 781
Natelson, B. H., 431, 633
Naumenko, E. V., 85
Naylor, R. J., 197, 573
Ng, K. T., 881, 889
Nichols, D. E., 105
Nichols, M. B., 181
Nikulina, E. M., 85
Nishimura, H., 227
Nolte, H. E., 815
Noonan, L. R., 555

O'Connor, C. S., 315
Ogle, C. W., 563
Onaivi, E. S., 197
Osborne, P. G., 335
Osman, M., 167
Ota, M., 371
Ottenweller, J. E., 431, 633
Özüari, A., 519

Packard, M. G., 511
Paez, X., 45
Panksepp, J., 533, 539
Parada, M. A., 45
Paul, S. M., 649
Pavone, F., 927
Pedersen, C. A., 555
Peris, J., 465
Perlanski, E., 493
Pierri, J., 205
Pivorun, E. B., 309
Płaźnik, A., 749, 755
Pohorecky, L. A., 55
Poling, A., 11, 777
Popova, N. K., 85
Pryor, G. T., 157
Przegaliński, E., 329
Puig, M. M., 459
Puig De Parada, M., 45

Quartermain, D., 51
Quinn, M. J., 75

Rabin, B. M., 847
Ramabadran, K., 459
Ramarao, P., 375
Ramsey Barcik, N., 545
Rayford, P. L., 591, 663
Rebert, C. S., 157
Rehnberg, B. G., 435
Reichlin, S., 585
Reid, L. D., 281, 765
Reilly, S., 219
Reiter, L. W., 415
Revusky, S., 219
Richardson, J. S., 435
Robel, P., 701
Roberts, P., 55
Romm, E., 679
Rose, J. E., 919
Rosenwasser, A. M., 291
Rowland, N. E., 401
Rusk, I. N., 21

Sadeghi, K. G., 601
Sagratella, S., 713
Sakurai-Yamashita, Y., 397
Samson, H. H., 601
Sansone, M., 927
Santucci, A. C., 485
Schechter, M. D., 299
Schlinger, H., 11, 777
Schwartz, D. H., 257
Schwartzenburg, D. S., 261
Scotti de Carolis, A., 713
Seale, T. W., 99
See, R. E., 501
Segal, R. B., 269
Seiden, L. S., 641
Serra, G., 81
Sharpe, L. G., 899
Sheets, L. P., 415
Shephard, R. A., 285
Sherer, M. A., 443, 829
Shimizu, T., 705
Shimosato, K., 423
Shirao, I., 477
Shishkina, G. T., 85
Shuster, L., 839
Silverman, P. B., 729
Simon, J. R., 349
Skolnick, P., 649
Sloley, B. D., 435
Smith, B. R., 269
Smith, R. J. F., 435
Sneddon, B., 493
Soar, J., 637
Solway, E., 493
South, D., 501
Spencer, K. R., 241
Spoerlein, M. T., 387
Stanley, B. G., 257
Starr, B. S., 41
Starr, M. S., 41
Stefański, R., 749, 755
Stein, L., 147
Steketee, J. D., 729
Stewart, R. B., 493
Stitzel, J. A., 667
Stitzer, M. L., 853
Strek, K. F., 241
Sueyoshi, K., 477
Sumners, C., 401
Swann, A. C., 729
Swerdlow, N. R., 595

Tabar, J., 139
Takahashi, M., 843
Tanaka, M., 227, 477
Tang, M., 393
Tapp, W. N., 431, 633
Taylor, A. N., 793
Tirelli, E., 497
Toide, K., 109
Tokuyama, S., 843
Tolliver, G. A., 601
Tomkins, D. M., 573
Torres, P., 115
Toth, E., 175
Tremblay, L. E., 127
Trujillo, K. A., 147
Tsuda, A., 227, 477
Turkish, S., 17
Turkkan, J. S., 923
Turndorf, H., 459

Ueki, S., 93, 397
Ukai, M., 355
Uphouse, L., 615

Vanderwende, C., 387
van Haaren, F., 361

Van Hartesveldt, C., 321
van Hattum, T., 361
van Hest, A., 361
Varga, M., 523
Vaupel, D. B., 245, 717
Vetulani, J., 927
Vosmer, G., 641

Wagner, K. R., 233
Wallin, L., 381
Warchol-Kania, A., 329
Warenycia, M. W., 489
Watanabe, S., 423
Weinhold, L. L., 853
Weisinger, R. S., 335
White, N. M., 511
Williams, J., 615
Wilmot, C. A., 387
Wise, R. A., 903
Wood, D. M., 453
Woolett, G. J., 913
Woolley, D. E., 787
Woolverton, W. L., 527
Wozniak, K. M., 265

Yang, S., 233
Yerbury, R. E., 303
Yirmiya, R., 793
Yoshida, H., 895
Young, E., 501
Young, G. A., 215

Zacny, J. P., 481, 527
Zagon, I. S., 325
Zahniser, N. R., 465
Zubrycki, E., 725